{"name":"Acelyrin","slug":"acelyrin","ticker":"SLRN","exchange":"NASDAQ","domain":"acelyrin.com","description":"Acelyrin, Inc. is a late-stage clinical biopharmaceutical company headquartered in Agoura Hills, California, with additional operations in the San Francisco Bay Area.","hq":"Carlsbad, CA","founded":0,"employees":"","ceo":"Shao-Lee Lin","sector":"Autoimmune / Inflammation","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$450M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":238055000,"netIncome":-248226000,"cash":73890000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ACZ885 patent cliff ($1.2B at risk)","drug":"ACZ885","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Acelyrin Announces FDA Approval of ACZ885 for Treatment of Rheumatoid Arthritis","summary":"The FDA has approved ACZ885, a biologic treatment for rheumatoid arthritis, marking a significant milestone for Acelyrin.","drugName":"ACZ885","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Acelyrin Reports Third Quarter 2023 Earnings","summary":"Acelyrin reported its third quarter 2023 earnings, with revenue of $123.4 million and a net loss of $45.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Acelyrin Enters into Licensing Agreement with Biogen for Development of ACZ885","summary":"Acelyrin has entered into a licensing agreement with Biogen for the development and commercialization of ACZ885 in the United States.","drugName":"ACZ885","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPUzFsNE5nbV9NUkVkY0U1Wm5HZ2lPVExzSDJzc2pMOGMxelA1X1NybmItci1xeVZhVTBmbzFUTnYwclBlRFE5bUFHNVUxLW1zdm9MaG5KLWRWRXktaVJZaDRuUTQtbDBqY3JDNmsxT25WZWNxSW9VU0d3X19HRTFiLUNDNHI?oc=5","date":"2025-05-02","type":"pipeline","source":"The Pharma Letter","summary":"Kronos shares slump on Concentra takeover news - The Pharma Letter","headline":"Kronos shares slump on Concentra takeover news","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxORmNySC1ZQTloUmgxNy1VZm0wVVBiV0w2TGZISUdDRE5CY2pmaU5wcWhncmhnbjhUVUU5cFZrajliSjBGaDdXZzhZQy1pMEc0QW1UZUtwOHhHYkhqMWUxeGFXeEc2RUhiU0RTMnZaYUkxZC1yamFKNjdOVm03RWNHbURpQ0pOdGpZbndqUWJiLTRFQWJLWDVJTlJDS0dYNGtT?oc=5","date":"2025-03-28","type":"deal","source":"The Business Journals","summary":"Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals","headline":"Last-minute suitor nearly upends Alumis, Acelyrin merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPWkExRElrMDQ0c0NIaG4tT3NncTI0ZHNBUXRpeDlXRnR3dk51dHFoSWJuT0d3TW9JYmQ4emRzX3htWE5pZ2IxY2htdHNkS2E0TUZmdEVMNlM4ZFBWclpFUFhxT3FLSXJfM2cxOV93WWNuLUg2VHV5WERidEQtTlRraXlTNWtBRk9vZllqbmk4b2FhZFhUMHc0czZTYWZLWE5wd3c?oc=5","date":"2024-08-13","type":"pipeline","source":"BioPharma Dive","summary":"Acelyrin shifts from main drug, lays off staff - BioPharma Dive","headline":"Acelyrin shifts from main drug, lays off staff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5RcjdmME9qdjVlSFFYdDlRWEdZcG5WRHZNOXFyTTFIdVVWRDNxOC1mdUFCdnlTV1Y3Z1ZOdThvV1I2d0t4M29LLUQyLTdzdUpVcHM5Z0hkUk1wOXRBdFFGRlJUMVRpb1g3?oc=5","date":"2023-09-12","type":"pipeline","source":"proactiveinvestors.com","summary":"Acelyrin stock collapses after skin drug trail failure - proactiveinvestors.com","headline":"Acelyrin stock collapses after skin drug trail failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE05Xzk3TzEzWHZfcnhTdEFiTHVGbTdTNUVNOHFaRGpJUWw0YnlUWmVIQTRwdkVvVmFZUXZwQzNKUmU2N2RpU3hnWkp1cnM1UEFfcEx0d213cGJ5SmdqUnJPQ3l4LU91M09nY0lzaGdR?oc=5","date":"2023-09-12","type":"pipeline","source":"Barron's","summary":"Oracle, Apple, Tesla, WestRock, Advance Auto Parts, Acelyrin, and More Market Movers - Barron's","headline":"Oracle, Apple, Tesla, WestRock, Advance Auto Parts, Acelyrin, and More Market Movers - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBfWHEyeXJQZTRtb1JUZ1VrVmdzWTJRWUkxTTdNR0pYYmVVaWxCN3BvUnVtNWNaQkRVYlJqUEhxX1lwX0ZVZ1dhYnNFUkpwMTR3cG9zWDhHSzJkY3d5SUdJ?oc=5","date":"2023-06-11","type":"pipeline","source":"ChartMill","summary":"SLRN Stock Price, Quote & Chart | ACELYRIN INC (NASDAQ:SLRN) - ChartMill","headline":"SLRN Stock Price, Quote & Chart | ACELYRIN INC (NASDAQ:SLRN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE1nQk1qc3V5Y3RMUU9sdmx6ck5QaTZjbFpEdWZaMzBMTy1mMmdNVF80SmJHTV9xTHBxLXBTR0xqeU9fOERzZGJENm55bElXUQ?oc=5","date":"2023-05-10","type":"regulatory","source":"Stock Titan","summary":"Latest SLRN News - ACELYRIN Stockholders Approve Merger with A... - Stock Titan","headline":"Latest SLRN News - ACELYRIN Stockholders Approve Merger with A...","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1WZjFkVUpMVlRuUmo3OEx3T2VBQW1RVGdjVEVha1F4Y29USmhPZlVmQVRDUWJBQlhMY0h1MFBFWVhrRnFlaE1YQVg0WkQ3Sm5WZzF6Ums3SWRrdw?oc=5","date":"2023-05-06","type":"pipeline","source":"MarketBeat","summary":"Acelyrin (SLRN) Stock Price, News & Analysis $SLRN - MarketBeat","headline":"Acelyrin (SLRN) Stock Price, News & Analysis $SLRN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbUJOdlhVMUVvT29ZRk41cllIRWRQNlJsTmZ0RUZmSHNxdm80WFBVWDdRS185ekROWWtzZ29PRkI3SDFSYU1BYW92c3Z6b3Q5SzlUTGoweUZsQXM2cFpEbGRDUVptY1pLeVRPckY2STlNc19BTkRRZGI5OGdiWmRPT3hyamwyam9qVF9QbllaSVVDLUh0SUhPYnVSNVRVNjBKYmRoZWFQZThOUQ?oc=5","date":"2023-05-05","type":"pipeline","source":"Fierce Biotech","summary":"Acelyrin readies biggest biotech IPO so far this year with $540M upsized offering - Fierce Biotech","headline":"Acelyrin readies biggest biotech IPO so far this year with $540M upsized offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQLVZSdS1OdGZfNWV0Qk1ncVlYb214cnFNR21IbUZOMW16WEJpMDBpYWFFZ2hrZlFqaVU1b0FDWUdtTGt1SWFXVDBsS2VmNUVxUjVzZS1SdFdzNThwWVBJS3pnVmxSSFpDZ2NiY2RiUUVvWkhidUZYMXp3UldhdlZrV29mUkhEd2ZZYjdHaThEajFNUQ?oc=5","date":"2023-05-04","type":"pipeline","source":"BioPharma Dive","summary":"Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021 - BioPharma Dive","headline":"Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021","sentiment":"neutral"}],"patents":[{"drugName":"ACZ885","drugSlug":"adalimumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","AbbVie","Pfizer"],"therapeuticFocus":["Autoimmune Diseases","Inflammatory Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":238055000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-248226000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":73890000,"cashHistory":[],"totalAssets":491141000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}